Challenges of CRISPR-Based Gene Editing in Primary T Cells
, Lea Fritz 1,†, Reinhold Förster 1,2,3,‡ and Berislav Bošnjak 1,*,‡Round 1
Reviewer 1 Report
The authors present a valuable review on the use of CRISPR/Cas technology in both research and medical practice with applications in adaptive T cell immunotherapy for malignancies and in immunosuppression management in transplant patients.
The subject chosen is of the highest relevance as this method has revolutionized research in biology. Optimization of protocols used for gene deletion or insertion led to high efficacy encouraging the use of genome edited T cells in clinical trials.
A synthetic description of the most current genome editing methods is followed by description of the CRISPR/Cas system, methodology of gene editing in T cells, research and clinical applications of different strategies using gene modifications in T cells.
The authors also present an overview of ongoing clinical studies using CRISPR-engineered T cells for patients with both malignant hemopathies and solid tumors.
I recommend the publication of the article in the present form.
Reviewer 2 Report
The authors have reviewed the current literature and described the genetic engineering in T cells via Crispr/Cas9. Overall, there is not much to be changed in the review article. The authors have done a good job in covering the latest developments in the field and are potentially acceptable in their current form.
